Hyderabad, India and Princeton, NJ, USA. April 7, 2021 – Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DR REDDY, NYSE: RDY, NSEIFSC: DR REDDY along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Sapropterin Dihydrochloride Powder for Oral Solution, 100mg, a therapeutic equivalent generic version of Kuvan® (sapropterin dihydrochloride) Powder for Oral Solution, 100 mg, USP, approved by the U.S. Food and Drug Administration (USFDA). “We are pleased to launch this generic version of Sapropterin Dihydrochloride Powder for Oral Solution, illustrating our continued commitment to bringing affordable generic medicines to market for patients,” says Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy’s Laboratories. “At the same time, this product demonstrates that we are actively expanding the breadth of our portfolio with a treatment for a rare disease.” Dr. Reddy’s Sapropterin Dihydrochloride Powder for Oral Solution is available in 100 mg unit dose packets in a 30 count carton.
Are you an aspiring enthusiast willing to develop a career in the medical sales field? The dynamic profile of a medical representative, their exponent...
A healthy gut indicates a healthy you! Isn't that true? In easy words, gut health refers to the balance of microorganisms present in your digestive sy...
Is the scorching sun heat taking a toll on your skin health? The summers trigger all skin types due to excessive humidity and heat around. Dermatologi...
